A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation

References

• Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95(4):644–650
   PubMed Web of Science ®Google Scholar
• Koehler P, Hamprecht A, Bader O, et al. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA study. Int J Antimicrob Agents. 2017;49(2):218–223
   PubMed Web of Science ®Google Scholar
• Lupianez CB, Canet LM, Carvalho A, et al. Polymorphisms in host immunity-modulating genes and risk of invasive aspergillosis: results from the AspBIOmics consortium. Infect Immun. 2015;84:643–657. doi: 10.1128/IAI.01359-15
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Bories P, Moulin JC, et al. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci. 2012;1272(1):23–30
   PubMedGoogle Scholar
• Oren I, Haddad N, Finkelstein R, et al. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol. 2001;66(4):257–262
   PubMed Web of Science ®Google Scholar
• Flynn PM, Williams BG, Hetherington SV, et al. Aspergillus terreus during hospital renovation. Infect Control Hosp Epidemiol. 1993;14(7):363–365
   PubMed Web of Science ®Google Scholar
• Caira M, Candoni A, Verga L, et al. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica. 2015 Feb;100(2):284–292. doi: 10.3324/haematol.2014.113399
   PubMed Web of Science ®Google Scholar
• Cornely OA, Gachot B, Akan H, et al. Epidemiology and outcome of fungemia in a cancer cohort of the infectious diseases group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 2015;61:324–331. doi: 10.1093/cid/civ293
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359
   PubMed Web of Science ®Google Scholar
• Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on infections in leukaemia. J Antimicrob Chemother. 2018;73:3221–3230. doi: 10.1093/jac/dky286
   PubMed Web of Science ®Google Scholar
• Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97(2):197–207
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(suppl 1):e1–38
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With CancerRelated Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. JCO. 2018;36:3043–55. doi: 10.1200/JCO.18.00374
   PubMed Web of Science ®Google Scholar
• Stemler J, Mellinghoff SC, Khodamoradi Y, et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother. 2023;78(8):1813–1826
   PubMed Web of Science ®Google Scholar
• Lipp HP. Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses. 2011;54(Suppl 1):32–38. doi:10.1111/j.1439-0507.2010.01984.x
   PubMed Web of Science ®Google Scholar
• Bui J, Gellatly R, Othman J, et al. Subtherapeutic concentrations of PCZ tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients. Leuk Lymphoma. 2022 Dec;63(14):3418–25. doi: 10.1080/10428194.2022.2126282
   PubMed Web of Science ®Google Scholar
• Hachem R, Assaf A, Numan Y, et al. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. Int J Antimicrob Agents. 2017;50:384–388. doi: 10.1016/j.ijantimicag.2017.03.021
   PubMed Web of Science ®Google Scholar
• Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacyand safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis. 2012;55:381e90. doi: 10.1093/cid/cis437
   Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201e11. doi: 10.1086/524669
   Web of Science ®Google Scholar
• Chong GL, Broekman F, Polinder S, et al. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: efficacy and cost effectiveness in real-life. Int J Antimicrob Agents. 2015;46:82–88. doi: 10.1016/j.ijantimicag.2015.02.023
   PubMed Web of Science ®Google Scholar
• Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46(9):1401–1408
   PubMed Web of Science ®Google Scholar
• Annino L, Chierichini A, Anaclerico B, et al. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia. Antimicrob Agents Chemother. 2013;57:2596–02. doi: 10.1128/AAC.00155-13
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837
   PubMed Web of Science ®Google Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primarytreatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–769. doi: 10.1016/S0140-6736(15)01159-9
   PubMed Web of Science ®Google Scholar
• Jenks JD, Salzer HJ, Prattes J, et al. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Des Devel Ther. 2018;12:1033–1044. doi: 10.2147/DDDT.S145545
   PubMed Web of Science ®Google Scholar
• Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2020;70(5):723–730
   PubMed Web of Science ®Google Scholar
• Bowen CD, Tallman GB, Hakki M, et al. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre. Mycoses. 2019;62(8):665–672
   PubMed Web of Science ®Google Scholar
• Rausch CR, DiPippo AJ, Jiang Y, et al. Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. Clin Infect Dis. 2022 Oct 29;75(9):1503–1510. doi: 10.1093/cid/ciac230
   PubMed Web of Science ®Google Scholar
• Wasylyshyn AI, Linder KA, Kauffman CA, et al. Invasive fungal disease in patients with newly diagnosed acute myeloid leukemia. J Fungi (Basel). 2021;7(9):761
   PubMedGoogle Scholar
• Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on infections in leukemia (ECIL). Leukemia. 2019 Apr;33(4):844–62. doi: 10.1038/s41375-019-0388-x
   PubMed Web of Science ®Google Scholar
• Stemler J, de Jonge N, Skoetz N, et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European hematology association. Lancet Haematol. 2022 May;9(5):e361–e373. doi: 10.1016/S2352-3026(22)00073-4
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):44224429
   Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228
   PubMed Web of Science ®Google Scholar
• Wei AH, SA S Jr., Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–84
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17
   PubMed Web of Science ®Google Scholar
• Chen CE, Liu Y, Harris CE, et al. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022 Aug;63(8):1934–41. doi: 10.1080/10428194.2022.2047964
   PubMed Web of Science ®Google Scholar
• On S, Rath CG, Lan M, et al. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. Br J Haematol. 2022 Apr;197(1):63–70. doi: 10.1111/bjh.18051
   PubMed Web of Science ®Google Scholar
• Aldoss I, Dadwal S, Zhang J, et al. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv. 2019;3:4043–4049. doi: 10.1182/bloodadvances.2019000930
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Stasi R, et al. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol. 2013;31(35):4424–4430
   PubMed Web of Science ®Google Scholar
• Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novo AML: final efficacy and safety updates from the openlabel, phase III ALFA-0701 trial. Haematologica. 2019;104:113. doi: 10.3324/haematol.2018.188888
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Bullinger L, Garcia-Vidal C, et al. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on infections in leukemia (ECIL), a joint venture of the European group for Blood and Marrow transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia. 2022 May;36(5):1215–26. doi: 10.1038/s41375-022-01556-7
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Marchesi F, Terrenato I, et al. High incidence of invasive fungal diseases in patients with FLT3-mutated AML treated with midostaurin: results of a multicenter observational SEIFEM study. J Fungi (Basel). 2022 May 29;8(6):583. doi: 10.3390/jof8060583
   PubMedGoogle Scholar
• Girmenia C, Lo Coco F, Breccia M, et al. Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. Leukemia. 2003 May;17(5):925–930. doi: 10.1038/sj.leu.2402899
   PubMed Web of Science ®Google Scholar
• Cosio T, Gaziano R, Zuccari G, et al. Retinoids in fungal infections: from bench to bedside. Pharmaceuticals (Basel). 2021 Sep 24;14(10):962. doi: 10.3390/ph14100962
   PubMedGoogle Scholar
• Campione E, Gaziano R, Doldo E, et al. Antifungal effect of all-trans retinoic acid against Aspergillus fumigatus in vitro and in a pulmonary aspergillosis in vivo model. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01874–20. doi: 10.1128/AAC.01874-20
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;1(91):1068–1075.
   Google Scholar
• Henden A, Morris K, Truloff N. Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis. Leuk Lymphoma. 2013;54(6):1329–1331. doi: 10.3109/10428194.2012.740561
   PubMed Web of Science ®Google Scholar
• Doan TN, Kirkpatrick CM, Walker P, et al. Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: A multicentre audit. J Antimicrob Chemother. 2016;71:497–505. doi: 10.1093/jac/dkv343
   PubMed Web of Science ®Google Scholar
• Mariette C, Tavernier E, Hocquet D, et al. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. Leuk Lymphoma. 2017;58(3):586–593
   PubMed Web of Science ®Google Scholar
• Di Blasi R, Cattaneo C, Lewis R, et al. Febrile events in acute lymphoblastic leukemia: A prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). Ann Hematol. 2018;97(5):791–798
   PubMed Web of Science ®Google Scholar
• Cornely OA, Kontoyiannis DP. How to prophylax against invasive fungal infections in adult ALL? An unmet need. Mycoses. 2018;61(9):646–649. doi: 10.1111/myc.12786
   PubMed Web of Science ®Google Scholar
• Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004;103(4):1557–1559
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687–710. doi: 10.1097/FTD.0b013e31815c16f5
   PubMed Web of Science ®Google Scholar
• Lindsay J, Teh BW, Micklethwaite K, et al. Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis. 2019;32(6):538–545
   PubMed Web of Science ®Google Scholar
• Cornely OA, Leguay T, Maertens J, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017;72(8):2359–2367
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474–2487
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847
   PubMed Web of Science ®Google Scholar
• Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018 Jan 4;131(1):121–130. doi: 10.1182/blood-2017-07-793760
   PubMed Web of Science ®Google Scholar
• Park JH, Andre Romero F, Taur Y, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-Cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis. 2018 Aug 1;67(4):533540. doi: 10.1093/cid/ciy152
   Web of Science ®Google Scholar
• Los-Arcos I, Iacobini G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021 Apr;49(2):215–31. doi: 10.1007/s15010-020-01521-5
   PubMed Web of Science ®Google Scholar
• Nosari A, Pioltelli ML, Riva M, et al. Invasive fungal infections in lymphoproliferative disorders: a monocentric retrospective experience. Leuk Lymphoma. 2014;55(8):1844–1848
   PubMed Web of Science ®Google Scholar
• Takaoka K, Nannya Y, Shinohara A, et al. A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma. Ann Hematol. 2014;93(10):1637–1644
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Bories P, Moulin JC, et al. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci. 2012;1272:23–30. doi: 10.1111/j.1749-6632.2012.06829.x
   PubMed Web of Science ®Google Scholar
• Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–1867
   PubMed Web of Science ®Google Scholar
• Nosari A. Infectious complications in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2012;4(1):e2012070. doi: 10.4084/mjhid.2012.070
   PubMedGoogle Scholar
• Nosari AM, Caira M, Pioltelli ML, et al. Hema e-chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections. Clin Microbiol Infect. 2013;19(8):757–762
   PubMed Web of Science ®Google Scholar
• Molteni A, Nosari A, Montillo M, et al. Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes. Haematologica. 2005;90:1145–1147.
   PubMed Web of Science ®Google Scholar
• Teh BW, Tam CS, Handunnetti S, et al. Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies. Blood Rev. 2018;32:499–507. doi: 10.1016/j.blre.2018.04.007
   PubMed Web of Science ®Google Scholar
• Little JS, Weiss ZF, Hammond SP. Invasive fungal infections and targeted therapies in hematological malignancies. J Fungi. 2021;7(12):1058–78. doi: 10.3390/jof7121058
   Web of Science ®Google Scholar
• Nucci M, Anaissie E. How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. Blood. 2014;124(26):3858–3869. doi: 10.1182/blood-2014-04-516211
   PubMed Web of Science ®Google Scholar
• Mühlemann K, Wenger C, Zenhäusern R, et al. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia. 2005;19(4):545–550
   PubMed Web of Science ®Google Scholar
• Teng JC, Slavin MA, Teh BW, et al. Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica. 2015;100(11):e462–6
   PubMed Web of Science ®Google Scholar
• Francis S, Karanth M, Pratt G, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107(5):1023–1033
   PubMed Web of Science ®Google Scholar
• Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27(1):136–141
   PubMed Web of Science ®Google Scholar
• Cerny T, Borisch B, Introna M, et al. Mechanism of action of rituximab. Anticancer Drugs. 2002;13(Suppl. S2):S3–S10
   PubMedGoogle Scholar
• Pagano L, Akova M, Dimopoulos G, et al. Risk assessment and prognostic factors for mouldrelated diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(Suppl. S1):i5–i14
   PubMedGoogle Scholar
• Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses. 2013;56(6):638–645
   PubMed Web of Science ®Google Scholar
• Latgé JP, Chamilos G. Aspergillus fumigatus and aspergillosis in 2019. Clin Microbiol Rev. 2020;33:e00140–18. doi: 10.1128/CMR.00140-18
   Web of Science ®Google Scholar
• Kurokawa T, Hase M, Tokuman N, et al. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol. 2011;29(1):5–9
   PubMed Web of Science ®Google Scholar
• Davis JS, Ferreira D, Paige E, et al. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. 2020;33(3):e00035–19
   PubMed Web of Science ®Google Scholar
• Baddley JW. Clinical risk factors for invasive aspergillosis. Med Mycol. 2011;49(S1):S7–S12. doi: 10.3109/13693786.2010.505204
   PubMed Web of Science ®Google Scholar
• Neofytos D, Lu K, Hatfield-Seung A, et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis. 2013;75(2):144–149
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) alliance registry. Clin Infect Dis. 2009;48(3):265–273
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Tay K, Wilson WH. Rituximab-Associated Neutropenia. Semin Hematol. 2010;47:180–186. doi: 10.1053/j.seminhematol.2010.01.009
   PubMed Web of Science ®Google Scholar
• Sarlo KM, Dixon BN, Ni A, et al. Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody. Leuk Lymphoma. 2019;61:364–369. doi: 10.1080/10428194.2019.1666378
   PubMed Web of Science ®Google Scholar
• van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): An open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015;16:1370–1379. doi: 10.1016/S1470-2045(15)00143-6
   PubMed Web of Science ®Google Scholar
• Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24:S71–S82. doi: 10.1016/j.cmi.2018.02.003
   PubMed Web of Science ®Google Scholar
• Lanini S, Molloy AC, Fine PE, et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 2011;9(1):36
   PubMedGoogle Scholar
• Pierpont TM, Limper CB, Past RK. Present, and future of rituximab—the world’s first Oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. doi: 10.3389/fonc.2018.00163
   PubMed Web of Science ®Google Scholar
• Jiang X, Mei X, Feng D, et al. Prophylaxis and treatment of Pneumocystis jiroveci pneumonia in Lymphoma patients subjected to rituximab-contained therapy: a systemic review and MetaAnalysis. PLoS One. 2015;10:e0122171. doi: 10.1371/journal.pone.0122171
   PubMed Web of Science ®Google Scholar
• Martin-Garrido I, Carmona EM, Specks U, et al. Pneumocystis pneumonia in patients treated with rituximab. Chest. 2013;144(1):258–265
   PubMed Web of Science ®Google Scholar
• Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397–2404
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749–1755
   PubMed Web of Science ®Google Scholar
• Byrd C, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in Previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223
   PubMed Web of Science ®Google Scholar
• Leblond V, Aktan M, Coll CMF, et al. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Haematologica. 2018;103(11):1889
   PubMed Web of Science ®Google Scholar
• Österborg A, Wierda WG, Mayer J, et al. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2015;170(1):40–49
   PubMed Web of Science ®Google Scholar
• Ujjani C, Ramzi P, Gehan E, et al. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2014;56:915–920. doi: 10.3109/10428194.2014.933217
   PubMed Web of Science ®Google Scholar
• Tse E, Leung RYY, Kwong YL. Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia. Ann Hematol. 2014;94:165–167. doi: 10.1007/s00277-014-2120-2
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554–3561
   PubMed Web of Science ®Google Scholar
• Lundin JI, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as firstline therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 2004;18:484–490. doi: 10.1038/sj.leu.2403258
   PubMed Web of Science ®Google Scholar
• Thursky A, Wort L, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol. 2006;132(1):3–12
   PubMed Web of Science ®Google Scholar
• Ruiz-Camps I, Aguilar-Company J. Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Ther Adv Infect Dis. 2021 Feb 19;8:2049936121989548. doi: 10.1177/2049936121989548
   Web of Science ®Google Scholar
• Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24:S53–S70. doi: 10.1016/j.cmi.2018.02.009
   PubMed Web of Science ®Google Scholar
• Weber ANR, Bittner Z, Liu X, et al. Bruton’s Tyrosine Kinase: an emerging key player in innate immunity. Front Immunol. 2017 Nov 8;8:1454. doi: 10.3389/fimmu.2017.01454
   PubMed Web of Science ®Google Scholar
• Fiorcari S, Maffei R, Vallerini D, et al. BTK inhibition impairs the innate response against fungal infection in patients with chronic lymphocytic leukemia. Front Immunol. 2020, Aug 28;11:2158. doi: 10.3389/fimmu.2020.02158
   PubMedGoogle Scholar
• Stadler N, Hasibeder A, Lopez PA, et al. The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation. Haematologica. 2017 May;102(5):e191–e194. doi: 10.3324/haematol.2016.152017
   PubMed Web of Science ®Google Scholar
• Ruchlemer R, Ben Ami R, Lachish T. Letter to the editor: ibrutinib for chronic lymphocytic leukemia. N Engl J Med. 2016;374:1592–1595.
   PubMedGoogle Scholar
• Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS Lymphoma. Cancer Cell. 2017;31(6):833–843.e5
   PubMed Web of Science ®Google Scholar
• Frei M, Aitken SL, Jain N, et al. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma. 2020;61(10):2488–2491
   PubMed Web of Science ®Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with singleagent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–745. doi: 10.1182/blood-2015-03-635326
   PubMed Web of Science ®Google Scholar
• Messina JA, Maziarz EK, Spec A, et al. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib. Open Forum Infect Dis. 2017 Feb 9;4(1):ofw261. doi: 10.1093/ofid/ofw261
   PubMed Web of Science ®Google Scholar
• Baron M, Zini JM, Belval TC, et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma. 2017;58(12):2981–2982
   PubMed Web of Science ®Google Scholar
• Chan TSY, Au-Yeung R, Chim CS, et al. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia. Ann Hematol. 2017;96(5):871–872
   PubMed Web of Science ®Google Scholar
• Arthurs B, Wunderle K, Hsu M, et al. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep. 2017;21:27. doi: 10.1016/j.rmcr.2017.03.011
   PubMed Web of Science ®Google Scholar
• Okamoto K, Proia LA, Demarais PL. Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis. 2016;2016:4642831. doi: 10.1155/2016/4642831
   PubMedGoogle Scholar
• Ahn IE, Jerussi T, Farooqui M, et al. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128(15):1940–1943.
   PubMed Web of Science ®Google Scholar
• Tillman BF, Pauff JM, Satyanarayana G, et al. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol. 2018;100(4):325–334.
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;66(1):140. doi: 10.1093/cid/cix687
   PubMed Web of Science ®Google Scholar
• Anastasopoulou A, DiPippo AJ, Kontoyiannis DP. Non-Aspergillus invasive mould infections in patients treated with ibrutinib. Mycoses. 2020;63(8):787–793. doi: 10.1111/myc.13120
   PubMed Web of Science ®Google Scholar
• Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–1959.
   PubMed Web of Science ®Google Scholar
• Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid Cancer. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67(5):687.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Luay M, Zhao Q, et al. Incidence and type of Opportunistic infections during ibrutinib treatment at a single academic center. Blood. 2017;130(Suppl_1):830
   Google Scholar
• Marchesini G, Nadali G, Facchinelli D. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. Br J Haematol. 2021;193(2):316–324. doi: 10.1111/bjh.17145
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in Previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–3452
   PubMed Web of Science ®Google Scholar
• Furman RR, Byrd JC, Owen RG, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. 2021 Nov;35(11):3201–3211. doi: 10.1038/s41375-021-01252-y
   PubMed Web of Science ®Google Scholar
• Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic waldenström macroglobulinemia: the ASPEN study. Blood. 2020 Oct 29;136(18):2038–2050. doi: 10.1182/blood.2020006844
   PubMed Web of Science ®Google Scholar
• Ryan CE, Cheng MP, Issa NC, et al. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Adv. 2020;4:1458. doi: 10.1182/bloodadvances.2020001678
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent Lymphoma. N Engl J Med. 2014;370(11):1008–1018
   PubMed Web of Science ®Google Scholar
• Bilancio A, Okkenhaug K, Camps M, et al. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood. 2006;107:642–650. doi: 10.1182/blood-2005-07-3041
   PubMed Web of Science ®Google Scholar
• Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of bcell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol. 2012;3:256. doi: 10.3389/fimmu.2012.00256
   PubMed Web of Science ®Google Scholar
• Bird ST, Tian F, Flowers N, et al. Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries. JAMA Oncol. 2020;6(2):248–254
   PubMed Web of Science ®Google Scholar
• Cuneo A, Barosi G, Danesi R, et al. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper. Hematol Oncol. 2019;37(1):3–14
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297–311
   PubMed Web of Science ®Google Scholar
• Infante MS, Fernández-Cruz A, Núñez L, et al. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: a multicentric real-world study. Cancer Med. 2021;10(21):7629–7640
   PubMed Web of Science ®Google Scholar
• Tey A, Mohan B, Cheah R, et al. Disseminated lomentospora prolificans infection in a patient on idelalisib rituximab therapy for relapsed chronic lymphocytic leukaemia. Ann Hematol. 2020;99:2455–2456. doi: 10.1007/s00277-020-04087-2
   PubMed Web of Science ®Google Scholar
• Ward LM, Peluso MJ, Budak JZ, et al. Opportunistic coinfection with Pneumocystis jirovecii and Coccidioides immitis associated with idelalisib treatment in a patient with chronic lymphocytic leukaemia. BMJ Case Rep. 2020;13(4):e234113
   PubMedGoogle Scholar
• Lafon-Desmurs B, Monsel G, Leblond V, et al. Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia. Med Mal Infect. 2017;47(4):293–296
   PubMed Web of Science ®Google Scholar
• Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016;128(3):331. doi: 10.1182/blood-2016-02-702761
   PubMed Web of Science ®Google Scholar
• Griggio V, Perutelli F, Salvetti C, et al. Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia. Front Immunol. 2020;11:2899. doi: 10.3389/fimmu.2020.594556
   Web of Science ®Google Scholar
• Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24(18):4371–4379
   PubMed Web of Science ®Google Scholar
• Agarwal S, DiNardo CD, Potluri J, et al. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. Clin Ther. 2017;39(2):359–367
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043–3054
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Marr KA, Anaissie EJ, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH alliance registry. J Infect. 2012;65(5):453–464
   PubMed Web of Science ®Google Scholar
• McLornan DP, Khan AA, Harrison CN. Immunological consequences of JAK inhibition: friend or foe? Curr Hematol Malig Rep. 2015;10(4):370–379. doi: 10.1007/s11899-015-0284-z
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):1–14
   PubMedGoogle Scholar
• Lussana F, Cattaneo M, Rambaldi A, et al. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93(3):339–347
   PubMed Web of Science ®Google Scholar
• Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143(5):1478–1479. doi: 10.1378/chest.12-1604
   PubMed Web of Science ®Google Scholar
• Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep. 2014 Jun 2;2014:bcr2014204950. doi: 10.1136/bcr-2014-204950
   PubMedGoogle Scholar
• Chan JFW, Chan TSY, Gill H, et al. Disseminated infections with talaromyces marneffei in non-AIDS patients given monoclonal antibodies against CD20 and kinase inhibitors. Emerg Infect Dis. 2015;21(7):1101–1106
   PubMed Web of Science ®Google Scholar
• Sylvine P, Thomas S, Pirayeh E. Infections associated with ruxolitinib: study in the French pharmacovigilance database. Ann Hematol. 2018;97(5):913–914. doi: 10.1007/s00277-018-3242-8
   PubMed Web of Science ®Google Scholar
• Pajares B, Torres E, Trigo JM, et al. Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin Transl Oncol. 2012;14(2):94–101
   PubMed Web of Science ®Google Scholar
• Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and metaanalysis. J Clin Oncol. 2007;25:5471–5489. doi: 10.1200/JCO.2007.12.3851
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A, et al. Fungal Infections in Recipients of Hematopoietic Stem Cell Transplants: Results of the SEIFEM B-2004 Study—Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis. 2007 Nov 1;45(9):1161–70. doi: 10.1086/522189
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091–1100
   PubMed Web of Science ®Google Scholar
• Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20(6):872–880
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 update. Bone Marrow Transplant. 2011 May;46(5):709–18. doi: 10.1038/bmt.2010.175
   PubMed Web of Science ®Google Scholar
• Girmenia C, Barosi G, Piciocchi A, et al. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20(8):1080–1088
   PubMed Web of Science ®Google Scholar
• Zhao YJ, Khoo A, Tan G, et al. Network metaanlysis and pharmacoeconomic evaluation of fluconazole, itraconazole, posaconazole and voriconazole in invasive fungal infection prophylaxis. Antimicrob Agents Chemother. 2016;60:376–86. doi: 10.1128/AAC.01985-15
   PubMed Web of Science ®Google Scholar
• Bow EJ, Vanness DJ, Slavin M, et al. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect Dis. 2015;15(1):128
   PubMedGoogle Scholar
• Lee CH, Lin C, Ho CL, et al. Primary fungal prophylaxis in hematological malignancy: a network meta-analysis of randomized controlled trials. Antimicrob Agents Chemother. 2018;62(8):e00355–18
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–347
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–5118
   PubMed Web of Science ®Google Scholar
• Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011 Nov;155(3):318–327. doi: 10.1111/j.1365-2141.2011.08838.x
   PubMed Web of Science ®Google Scholar
• Teh BW, Yeoh DK, Haeusler GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation. Intern Med J. 2021 Nov;51(Suppl 7):67–88. doi: 10.1111/imj.15588
   PubMedGoogle Scholar
• López-Sánchez C, Valcárcel D, Gómez V, et al. Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC). Rev Esp Quimioter. 2020;33(2):110–115
   PubMed Web of Science ®Google Scholar
• Wingen-Heimann SM, Cornely OA, Vehreschild M, et al. Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: a six-year cohort analysis. Mycoses. 2021;64(4):437–444
   PubMed Web of Science ®Google Scholar
• Vehreschild MJ, von Bergwelt-Baildon M, Tran L, et al. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients. Eur J Haematol. 2014;93:400–406. doi: 10.1111/ejh.12368
   PubMed Web of Science ®Google Scholar
• Wang CH, Kan LP, Lin HA, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients: a retrospective analysis of a single medical center in Taiwan. J Microbiol Immunol Infect. 2016;49:531–538. doi: 10.1016/j.jmii.2014.07.009
   PubMedGoogle Scholar
• Dolton MJ, Ray JE, Chen SCA, et al. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012;56(11):5503–5510
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Marriott D, et al. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(6):2806–2813
   PubMed Web of Science ®Google Scholar
• Greco R, Barbanti MC, Lupo Stranghellini MT, et al. Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2016;51(7):1022–1024
   PubMed Web of Science ®Google Scholar
• Stern A, Su Y, Lee YJ, et al. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Jun;26(6):1195–1202. doi: 10.1016/j.bbmt.2020.02.009
   PubMed Web of Science ®Google Scholar
• Ping Y, Hongmei J, Bellmann C, et al. Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting. Hematology. 2022 Dec;27(1):723–732. doi: 10.1080/16078454.2022.2076046
   PubMed Web of Science ®Google Scholar
• Vu CA, Rana MM, Jacobs SE, et al. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: a single-center experience. Transpl Infect Dis. 2021 Apr;23(2):e13469. doi: 10.1111/tid.13469
   PubMed Web of Science ®Google Scholar
• Lahmer T, Peçanha-Pietrobom PM, Schmid RM, et al. Invasive fungal infections in acute and chronic liver impairment: A systematic review. Mycoses. 2022 Feb;65(2):140–151. doi: 10.1111/myc.13403
   PubMed Web of Science ®Google Scholar
• Batista MV, Ussetti MP, Jiang Y, et al. Comparing the real-world use of Isavuconazole to other anti-fungal therapy for invasive fungal infections in patients with and without underlying disparities: a multi-center retrospective study. J Fungi (Basel). 2023 Jan 27;9(2):166. doi: 10.3390/jof9020166
   PubMedGoogle Scholar
• Ong V, Hough G, Schlosser M, et al. Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin. Antimicrob Agents Chemother. 2016;60(11):6872–6879
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G. Rezafungin-mechanisms of action, Susceptibility and resistance: similarities and differences with the other echinocandins. J Fungi. 2020;6:262. doi: 10.3390/jof6040262
   Web of Science ®Google Scholar
• Miesel L, Cushion MT, Ashbaugh A, et al. Efficacy of rezafungin in prophylactic mouse models of invasive candidiasis, aspergillosis, and Pneumocystis pneumonia. Antimicrob Agents Chemother. 2021;65(3):e01992–20
   PubMed Web of Science ®Google Scholar
• Colley T, Alanio A, Kelly SL, et al. In vitro and in vivo antifungal profile of a novel and longacting inhaled azole, PC945, on Aspergillus fumigatus infection. Antimicrob Agents Chemother. 2017;61(5):e02280–16
   PubMed Web of Science ®Google Scholar
• Cass L, Murray A, Davis A, et al. Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. Pharmacol Res Perspect. 2021;9(1):e00690
   PubMed Web of Science ®Google Scholar
• Walker SS, Xu Y, Triantafyllou I, et al. Discovery of a novel class of orally active antifungal beta-1,3-d-glucan synthase inhibitors. Antimicrob Agents Chemother. 2011;55(11):5099–5106
   PubMed Web of Science ®Google Scholar
• Barat S-EK, Angulo D, Ashbaugh A, et al. Efficacy of ibrexafungerp (formerly SCY-078) in a murine treatment model of Pneumocystis pneumonia. ASM MicrobeJune 20–24, 2019; San Francisco CA; 2019
   Google Scholar
• Schell WA, Jones AM, Borroto-Esoda K, et al. Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species. Antimicrob Agents Chemother. 2017;61(11):e01102–17
   PubMed Web of Science ®Google Scholar
• Jiménez-Ortigosa C, Paderu P, Motyl MR, et al. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother. 2014;58(2):1248–1251
   PubMed Web of Science ®Google Scholar